Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25290010 | 0.83 | CYP19A1 (0.40) | CYP19A1 | |
| SCHEMBL25874588 | 0.80 | EPHA2 (0.41) | EPHA2P2RX3P2RX2ERBB2EPHB4 | |
| SCHEMBL30588379 | 0.77 | EPHA2 (0.43) | EPHA2USP30ERBB2EPHB4USP2 | |
| SCHEMBL30588147 | 0.77 | EPHA2 (0.43) | EPHA2USP30ERBB2EPHB4USP2 | |
| SCHEMBL16885204 | 0.77 | EPHA2 (0.46) | EPHA2USP30P2RX3P2RX2ERBB2 | |
| SCHEMBL16876583 | 0.77 | EPHA2 (0.46) | EPHA2USP30P2RX3P2RX2ERBB2 | |
| SCHEMBL16876582 | 0.77 | EPHA2 (0.46) | EPHA2USP30P2RX3P2RX2ERBB2 | |
| SCHEMBL5288704 | 0.75 | USP2 (0.51) | EPHA2ERBB2EPHB4USP2SMN1; SMN2 | |
| SCHEMBL2444420 | 0.75 | USP2 (0.51) | EPHA2ERBB2EPHB4USP2SMN1; SMN2 | |
| SCHEMBL5287268 | 0.75 | USP2 (0.51) | EPHA2ERBB2EPHB4USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | EPHA2 4163/4885USP30 6/4885P2RX3 4108/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | EPHA2 4163/4885USP30 6/4885P2RX3 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.